Anthera Presents Data on Varespladib at ATVB Meeting
SAN MATEO, Calif., April 17, 2008 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that Anthera scientists and collaborators have released data from the Varespladib (A-002) clinical and pre-clinical programs at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Annual Conference in Atlanta, Georgia, held on April 16-18, 2008. Anthera has completed Phase II trials in Varespladib for the treatment of coronary heart disease.
Posters include: -- Effects of a Selective Secretory Phospholipase A2 Inhibitor on Low-Density Lipoproteins in CHD Patients with Diabetes. -- The Synergistic Inhibition of Atherogenesis in ApoE-/- Mice Between Pravastatin and the sPLA2 Inhibitor Varespladib (A-002).
"We are pleased to see the synergistic effect of Varespladib with statins on plaque reduction, composition and stability in a well established model of atherosclerosis," said Joaquim Trias, Ph.D., Senior Vice President of Preclinical Development at Anthera Pharmaceuticals, Inc.
"Along with the Phase II PLASMA data presented at ACC earlier this year, today's announcement gives us added confidence as we move the Varespladib clinical program forward," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "These findings further support our clinical development program as we begin Phase III clinical trials in patients with acute coronary syndromes where inflammation, atherosclerosis and cholesterol levels are highly correlated with outcomes."
Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.Â? Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienesÂ? prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novelÂ? upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com
INVESTOR AND MEDIA CONTACT: Anne Bowdidge (650) 218-6900 firstname.lastname@example.org
CONTACT: Anne Bowdidge of Anthera Pharmaceuticals, Inc., +1-650-218-6900, email@example.com
Web site: http://www.anthera.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2008